BridgeBio Pharma, Inc.

NASDAQ:BBIO

Biotechnology

Healthcare
$78.01 +1.13%

+$0.75 today

Market cap
$15.20B
Beta
0.97
P/E (TTM)
-18.1
EPS (TTM)
-$3.73
52W Low $40.19High $84.94

Volume 3.55M

Average 2.49M

BBIO Income Tax Expense

Income taxes recognized for the period, including current and deferred tax.

BridgeBio Pharma, Inc.NASDAQ: BBIO

Income Tax Expense · Q2 FY2026 · quarter ended Jun 2026

Income tax expense remains negative

Q2 FY2026 income tax expense was $0, compared with $2.1M a year earlier. Trailing-twelve-month income tax expense was -$1.55M.

Context

  • Income tax expense amounted to 0.1% of revenue in FY2025, down 0.4 pp from a year earlier.
  • Income tax expense increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly income tax expense holds near $0 or moves back toward the trailing-twelve-month quarterly average of -$386.25K.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$0— QoQ
Last fiscal yearDec 2025
$555K-51.9% YoY
LTMJun 2026
-$1.55M-147.5% YoY
Income Tax Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-100.0%——
1 year-51.9%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Income Tax Expense history

USD · from the income statement

Latest · FY2025
555K USD
Year-over-year change
-51.9%

Income Tax Expense vs competitors

How BBIO compares with its peers on the latest reported figures

  • Peers report in different currencies, so income tax expense is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -147.5% is the 7th highest of 10, against a peer median of +34.3%.
  • Income tax expense amounts to 0.2% of revenue for BBIO, versus a peer median of 0.8%.
BBIO Competitors
Income Tax Expense for BBIO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
TVTXTravere Therapeutics, Inc.LTM Sep 2026$6.49M USD+129940.0%+46.7%1.0%
RAREUltragenyx Pharmaceutical Inc.LTM Mar 2026$3.82M USD+55.8%-11.1%0.6%
DNLIDenali Therapeutics Inc.LTM Jun 2026$102K USD+50.0%+69.4%2.8%
SRRKScholar Rock Holding CorporationLTM Sep 2026$0 USD——0.0%
MAZEMaze Therapeutics, Inc.LTM Mar 2026$0 USD-100.0%—0.0%
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026-$187K USD+92.1%-56.0%0.0%
BBIOBridgeBio Pharma, Inc.LTM Jun 2026-$1.55M USD-147.5%—0.2%
PTCTPTC Therapeutics, Inc.LTM Jun 2026-$28.69M USD-177.7%—2.8%
ALNYAlnylam Pharmaceuticals, Inc.LTM Jun 2026-$39.75M USD+34.3%+31.2%0.8%
ASNDAscendis Pharma A/SLTM Sep 2026-€619.19M EUR-6542.6%+40.1%51.2%
BMRNBioMarin Pharmaceutical Inc.LTM Sep 2026-$8.87B USD-5681.4%+155.4%0.9%
Peer median (excluding BBIO) —+34.3%+40.1%0.8%

Competitors are the stored peer set for BBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue69.72M77.65M9.3M221.9M502.08M
Cost of Revenue3.11M3.43M2.45M3.88M28.27M
Gross Profit66.6M74.21M6.86M218.02M473.81M
Gross Margin95.5%95.6%73.7%98.3%94.4%
Research & Development451.02M399.46M455.71M506.46M477.54M
Selling, General & Admin192.21M143.19M150.59M288.93M555.14M
Operating Expenses643.23M586.42M614.23M811M1.04B
Depreciation & Amortization5.84M6.77M6.49M6.08M5.43M
EBITDA(533.83M)(397.44M)(565.47M)(436.83M)(676.45M)
EBITDA Margin-765.7%-511.9%-6078.3%-196.9%-134.7%
Operating Income(576.63M)(512.2M)(607.37M)(592.97M)(569.09M)
Operating Margin-827.1%-659.6%-6528.8%-267.2%-113.3%
Interest Income1.13M7.54M18.04M17.25M19.85M
Interest Expense46.78M80.44M81.29M99.29M53.1M
Other Income / Expenses(9.82M)27.55M(45.88M)50.78M(165.9M)
Income Before Tax(586.45M)(484.65M)(653.25M)(542.19M)(734.99M)
Pre-Tax Margin-841.2%-624.2%-7021.9%-244.3%-146.4%
Income Tax Expense0001.15M555K
Net Income(562.54M)(481.18M)(643.2M)(535.76M)(729.31M)
Net Margin-806.9%-619.7%-6913.9%-241.4%-145.3%
EPS (Basic)(3.90)(3.35)(3.95)(2.88)(3.79)
EPS (Diluted)(3.90)(3.35)(3.95)(2.88)(3.79)
Weighted Avg Shares144.36M147.47M162.79M186.08M197.24M
Weighted Avg Shares (Diluted)144.36M147.47M162.79M186.08M197.24M

BridgeBio Pharma, Inc.

NASDAQ:BBIO

Intrinsic Alpha fair value

Locked

Current Price

$78.01

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.